追风透骨丸联合艾拉莫德治疗类风湿性关节炎的临床研究

目的探讨追风透骨丸联合艾拉莫德片治疗类风湿性关节炎的临床疗效。方法选取2014年3月—2018年3月在成都市新都区人民医院治疗类风湿性关节炎患者102例,根据用药的差别分为对照组(51例)和治疗组(51例)。对照组饭后口服艾拉莫德片,25 mg/次,2次/d;治疗组在对照组基础上饭后口服追风透骨丸,6 g/次,2次/d。两组患者均治疗24周。观察两组患者临床疗效,同时比较治疗前后两组患者关节肿胀分级、20 m步行时间、WOMAC、VAS和DAS28评分及血清学指标。结果治疗后,对照组和治疗组临床有效率分别为76.47%和94.12%,两组比较差异均具有统计学意义(P0.05)。治疗后,两组患者关节肿胀分级显著降低(P0.05),20 m步行时间显著缩短(P0.05),且治疗组患者关节肿胀分级明显低于对照组(P0.05),20 m步行时间明显短于对照组(P0.05)。治疗后,两组WOMAC评分、VAS评分、DAS28评分均显著降低(P0.05),且治疗组WOMAC、VAS和DAS28评分明显低于对照组(P0.05)。治疗后,两组患者C反应蛋白(CRP)、白细胞介素-6(IL-6)、IL-17、类风湿因子(RF)、环氧化酶-2(COX-2)和红细胞沉降率(ESR)水平均显著降低(P0.05),且治疗组这些血清学指标明显低于对照组(P0.05)。结论追风透骨丸联合艾拉莫德片治疗类风湿性关节炎可有效改善患者临床症状,降低血清细胞因子水平,改善关节疼痛,提高患者生活质量。

Clinical study on Zhuifeng Tougu Pills combined with ilamodide in treatment of rheumatoid arthritis

Objective To explore the clinical effect of Zhuifeng Tougu Pills combined with ilamodide in treatment of rheumatoid arthritis. Methods Patients (102 cases) with rheumatoid arthritis in Xindu People''s Hospital of Chengdu from March 2014 to March 2018 were divided into control (51 cases) and treatment (51 cases) groups based on different treatments. Patients in the control group were po administered with Iguratimod Tablets after meals, 25 mg/time, twice daily. Patients in the treatment group were po administered with Zhuifeng Tougu Pills on the basis of the control group after meals, 6 g/time, twice daily. Patients in two groups were treated for 24 weeks. After treatment, the clinical efficacy was evaluated, and the joint swelling grade, 20 m walking time, WOMAC, VAS and DAS28 scores, and the serological indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 83.7% and 95.9%, respectively, and there were differences between two groups (P<0.05). After treatment, the joint swelling grade and 20 m walking time in two groups were significantly decreased (P<0.05), and the joint swelling grade in the treatment group was significantly lower than that in the control group (P<0.05), 20 m walking time in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the WOMAC, VAS and DAS28 scores in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum CRP, RF, ESR, IL-6, IL-17 and COX-2 levels in two groups were significantly decreased (P<0.05), and these serological indicators in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Zhuifeng Tougu Pills combined with ilamodide in treatment of rheumatoid arthritis can effectively improve the clinical symptoms, reduce serum cytokine levels, improve joint pain and the quality of life..